O-010Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program

Introduction: Most esophageal squamous cell cancer (ESCC) patients (pts) have advanced disease at time of diagnosis. Chemotherapy (CTX) improved overall survival (OS), but still with limited impact. Prior studies suggested increased efficacy of EGFR antibodies (AB) combined with cisplatin (C) / 5-fluorouracil (F).